Announcements Trials
Browse Landscape

Phase

Phase 2 34Phase 1/2 25Phase 1 22Phase NA 7Phase EARLY_PHASE1 3Phase 3 3Phase 4 2Phase 2/3 1

Status

Completed 24Terminated 11Recruiting 7Withdrawn 3Unknown 3Not yet recruiting 3Active not recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Sarcoma 1Lymphoid 1Head & Neck 1

Conditions

Breast Neoplasms 15Neoplasms 11Pancreatic Neoplasms 10Prostatic Neoplasms 7Glioma 6Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Sarcoma 4Polycystic Ovary Syndrome 4Colonic Neoplasms 4Obesity 3Neoplasm Metastasis 3Multiple Myeloma 3Melanoma 3Lung Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 3Brain Neoplasms 3Pain, Postoperative 2Lymphoma 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Depression 2Cholangiocarcinoma 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2

Interventions

tremelimumab 1durvalumab 1Nivolumab 1Gene Expression Profiling 1Fluvastatin 1Base Sequence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Withdrawn × Melanoma × Clear all
NCT04891718 2022-07-08

CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

Presage Biosciences

Phase EARLY_PHASE1 Withdrawn
DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT04223648 2021-11-22

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Yale University

Phase EARLY_PHASE1 Withdrawn
Dermatologic

Melanoma

NCT04285749 2020-07-27

Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡